– USA, NY – Harris & Harris Group, Inc. (NASDAQ:TINY), an investor in transformative companies enabled by disruptive science, announced today that its Nominating Committee and Board of Directors have nominated Kevin Rendino for election to its Board of Directors at its upcoming Annual Meeting of Shareholders on June 7, 2016. Mr. Rendino was suggested to the company by one of its institutional shareholders, Lone Star Value Management, LLC.
Kevin Rendino is the President and CEO of RGJ Capital, LLC, a fund focused on investing in securities that are undervalued relative to the future true worth of their underlying assets. Prior to this, Mr. Rendino served as Portfolio Manager and Managing Director at BlackRock, Inc., where he was head of the Basic Value Equity Group ($10 to $13 billion in assets), as well as being a member of BlackRock’s Leadership Committee. Mr. Rendino joined BlackRock in 2006, following its merger with Merrill Lynch Investment Managers. His career began with Merrill Lynch in 1988, where he held various roles, including Managing Director, Portfolio Manager and heading the Basic Value Group. A well-respected member of the investment community, Mr. Rendino has been a frequent contributor to CNBC, Bloomberg TV, Fox Business and other financial newspapers and magazines, including the New York Times and the Wall Street Journal. Since 2014, Mr. Rendino has been Board Chair of Partners for Health, a public charity based in Montclair, NJ. The Foundation’s focus areas include: hunger and homelessness; policy and environmental changes that promote healthy people in healthy places; aging in our communities and mental health. Partners for Health has awarded grants totaling more than $7 million to 60 organizations, congregations, school districts and municipalities. He joined the Board in 2011. Mr. Rendino received his BS in Finance with high honors from the Carroll School of Management at Boston College.
“Kevin has demonstrated success investing in undervalued securities and realizing value in these investments. We believe this experience will be valuable for Harris & Harris Group and its investors,” said Douglas Jamison, Chief Executive Officer of Harris & Harris Group. “Additionally, he brings relevant experience related to our focus on precision health and the changing healthcare system.”
“I am delighted to join the Board of Harris & Harris Group. The Company has the necessary components to create significant value for all its shareholders, and I look forward to working with its Board and management team to realize this value,” said Kevin Rendino. “Over my nearly 30 years of investing, I have consistently been an advocate for management teams and boards being aligned with its shareholders. To that end, and in compliance with the Company’s policies and procedures, I intend to make open market purchases of Harris & Harris Group stock over the ensuing 18 months.”
About Harris & Harris Group
Harris & Harris Group is a publicly traded, internally managed business development company that builds transformative companies from disruptive science. Detailed information about Harris & Harris Group.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.